PERSONALIS INC (PSNL)       2.54  +0.23 (+9.96%)

2.54  +0.23 (+9.96%)

US71535D1063 - Common Stock - After market: 2.54 0 (0%)


Fundamental Rating

3

Taking everything into account, PSNL scores 3 out of 10 in our fundamental rating. PSNL was compared to 65 industry peers in the Life Sciences Tools & Services industry. The financial health of PSNL is medium. Also its profitability is quite bad. PSNL has a expensive valuation and it also scores bad on growth




Profitability

Profitability Rating

1

PSNL has negative profitability rations, so we won't be analyzing them here.
PSNL's Return On Assets of -32.23% is worse than the rest of the industry. The industry average Return On Assets is -16.45%.

PSNL has a Profit Margin of -148.46%. This is below the industry average of -29.71%. 82% of the industry peers outperform PSNL.
PSNL has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of PSNL.
VS Industry

ROA (-32.23%) VS Industry: 28% outperformed.

-620.54
57.39

Profit Margin (-148.46%) VS Industry: 18% outperformed.

-91,548.81
383.95

Valuation

Valuation Rating

3

When comparing the current price to the book value of PSNL, it is valued rather cheaply. It is trading at 0.48 times its book value.
Compared to an average industry price book ratio of 2.43, PSNL is valued rather cheaply. On top of this, PSNL is cheaper than 93% of the companies listed in the same industry.
Compared to an average Enterprise Value to EBITDA ratio of 15.51, PSNL is valued rather cheaply. On top of this, PSNL has a better ratio than 81% of the companies listed in the same industry.

PSNL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PSNL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry

Price/Book (0.48) VS Industry: 93% outperformed.

53.45
0.25

Enterprise Value/ EBITDA (2) VS Industry: 81% outperformed.

652.00
0.28

Growth

Growth Rating

3

PSNL shows a strong growth in Revenue. Measured over the last 5 years, the Revenue has been growing by 31.30% yearly.
PSNL is expected to show quite a strong growth in Revenue. In the coming 5 years, the Revenue will grow by 12.90% yearly.
The earnings per share for PSNL have decreased strongly by -64.96% in the last year.

PSNL is expected to show a very negative growth in Earnings Per Share. In the coming 5 years, the EPS will decrease by -11.12% yearly.
Looking at the last year, PSNL shows a very negative growth in Revenue. The Revenue has decreased by -18.81% in the last year.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -64.96% -73.68% -33.13% -17.47% -11.12%
RevenueN/A 31.3% -18.81% -24.58% -2.45% 10.06% 12.9%

Health

Health Rating

4

A Current Ratio of 6.58 indicates that PSNL has no problem at all paying its short term obligations.
The Current Ratio of PSNL is much better than the industry average of 4.86.
A Quick Ratio of 6.35 indicates that PSNL has no problem at all paying its short term obligations.
When comparing the Quick Ratio to an average industry Quick Ratio of 4.30, PSNL is better placed than the average industry peer to meet its short term obligations.

With a Debt to Equity ratio of 0.00, PSNL is doing better than the averages in the industry. The industry average is at 0.11.
Based on the Altman-Z score of -0.76, we must say that PSNL is in the distress zone and has some risk of bankruptcy.
Compared to an average industry Altman-Z score of 2.26, PSNL is in worse financial state than most of its industry peers. 82% of its industry peers have a better Altman-Z score.
PSNL has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of PSNL.
VS Industry

Debt/Equity (0) VS Industry: 70% outperformed.

3.88
0.00

Quick Ratio (6.35) VS Industry: 73% outperformed.

0.23
40.60

Current Ratio (6.58) VS Industry: 71% outperformed.

0.23
40.60

Altman-Z (-0.76) VS Industry: 18% outperformed.

-119.87
27.51

Dividend

Dividend Rating

0

No dividends for PSNL!.

PSNL Daily chart

PERSONALIS INC2.54

NASDAQ:PSNL (11/30/2022, 7:00:01 PM)+0.23 (+9.96%)

After market: 2.54 0 (0%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Life Sciences Tools & Services
Earnings (Last) 11-02 2022-11-02/amc Earnings (Next) 02-22 2023-02-22
Ins Owners 2.66% Inst Owners 61.01%
Market Cap 116.77M Analysts 83.08
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S 1.69 P/B 0.48
EV/EBITDA 2
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y -64.96% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -45%
EPS Next Y -73.68% EPS Next 2Y -33.13%
EPS Next 3Y -17.47% EPS Next 5Y -11.12%
Revenue growth 1Y -18.81% Revenue growth 3Y 31.3%
Revenue growth 5Y N/A Revenue growth Q2Q -33.26%
Revenue Next Year -24.58% Revenue Next 2Y -2.45%
Revenue Next 3Y 10.06% Revenue Next 5Y 12.9%
Health
Current Ratio 6.58 Quick Ratio 6.35
Altman-Z -0.76 F-Score 3
Debt/Equity 0 WACC 9.86%
ROIC/WACC N/A
Profitability
ROA -32.23% ROE N/A
ROICexgc N/A ROIC N/A
PM -148.46% OM -150.23%
Asset Turnover 0.22

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA